Stocky turns companies like Avanos Medical, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. AVNS lacks the growth or profitability to justify a 25× multiple: just 23/100 Growth Compounder Score with modest revenue momentum, and 28/100 Value Compounder Score reflecting thin margins. Leadership alignment at 59/100 suggests moderate incentive misalignment. The 50/100 Vulnerability Index indicates financial resilience is adequate but narrow—limited downside cushion if execution falters. Valuation is the core risk.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Avanos Medical, Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 40/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Avanos Medical, Inc. (AVNS) at 40/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. AVNS lacks the growth or profitability to justify a 25× multiple: just 23/100 Growth Compounder Score with modest revenue momentum, and 28/100 Value Compounder Score reflecting thin margins. Leadership alignment at 59/100 suggests
AVNS's current Stocky Verdict is 40/100, placing it in the "Cautious" band. This composite combines a 28/100 Compounder score, 59/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Avanos Medical, Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Avanos Medical, Inc. scores 59/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Avanos Medical, Inc.'s Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Avanos Medical, Inc..
Sign up free and unlock the full analysis on AVNS — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for AVNS in the app.
